GlassScriptPhysician profile
Michelle Johnston
NPI 1356549133
$18,215.28
in general payments reported to CMS, 2019-2025
32 companies · $3,336 in 2025
The $3,336 reported for 2025 was more than what 98% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,588 · 2022: $3,489 · 2023: $4,102 · 2024: $4,699 · 2025: $3,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Travel and Lodging: $1,798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,339.13 |
| Travel and Lodging | $1,798.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $8,300.24 | 2021-2025 | Merlin@Home, Advisor, Assurity |
| Boston Scientific Corporation | $2,341.31 | 2021-2025 | Watchman Access System, Bodyguardian, Latitude Communicator Power Supply |
| Atricure, INC. | $1,942.47 | 2024-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Biosense Webster, INC. | $1,353.16 | 2023-2025 | Carto 3, Nuvision Ice Catheter, Octaray Mapping Catheter |
| Impulse Dynamics (USA) INC. | $681.32 | 2021-2025 | Optimizer, Optimizer |
| Gilead Sciences, INC. | $545.08 | 2023-2025 | Epclusa, Vemlidy |
| Medtronic, INC. | $271.88 | 2022-2025 | Affera Mapping System, Selectsecure, Attain Command + Surevalve |
| Silk Road Medical, INC. | $267.50 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Inspire Medical Systems, INC. | $226.56 | 2023-2024 | Inspire |
| Genzyme Corporation | $218.31 | 2023-2024 | |
| Elutia, INC. | $211.73 | 2021-2022 | |
| Abbvie INC. | $188.86 | 2024-2025 | |
| Irhythm Technologies, INC. | $185.57 | 2024 | Zio Xt Patch, Zio Monitor |
| Madrigal Pharmaceuticals | $139.99 | 2025 | Rezdiffra |
| Csl Behring | $124.64 | 2024 | Hizentra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $121.86 | 2025 | Saphnelo |
| Corcept Therapeutics | $113.35 | 2025 | Korlym |
| Novo Nordisk INC | $97.21 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $93.62 | 2022 | |
| Edwards Lifesciences Corporation | $89.89 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $87.51 | 2021 | |
| Mylan Specialty L.P. | $85.09 | 2023 | Yupelri |
| Abiomed | $82.00 | 2025 | |
| Biogen, INC. | $76.29 | 2023 | |
| Pfizer INC. | $74.38 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $73.96 | 2021-2022 | |
| Coloplast Corp | $69.97 | 2024 | |
| Sanofi-Aventis U.S. LLC | $45.76 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $44.53 | 2025 | Lifevest |
| Cardiva Medical, INC. | $26.81 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Amgen INC. | $20.75 | 2021 | |
| Convatec INC. | $13.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.